Mutual regulation of Crl and Fur in Escherichia coli W3110.

The small regulatory protein Crl controls the expression of curli. Recently we have shown that Crl interacts directly with one of the most global regulators of Escherichia coli, the stress-related sigma factor RpoS, suggesting a more global role for Crl. We show here by a proteomics analysis that the expression of at least nine cellular proteins was considerably modified when Crl was overexpressed. We assessed the part of transcriptional and post-transcriptional regulation for five of these genes. The results showed that Crl regulates the expression of another global regulator, the central regulator of iron homeostasis, Fur. A molecular analysis revealed that Crl and Fur affect their own and each other's expression. We provide physical evidence for the binding of Fur to the crl and fur promoter regions. Crl modulated the affinity of Fur at the fur promoter but not at the crl promoter. The triad RpoS-Crl-Fur may thus represent the centerpiece of a global regulatory system of response to different stresses.

Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression.

Pharmacologic gene regulation is a key technology, necessary to achieve safe, long-term gene transfer. The approaches described in the scientific literature all share in common the creation of artificial transcription factors by fusing a DNA-binding domain, a drug-binding domain and a transcription activation domain. These transcription factors activate the transgene expression upon binding of the pharmacologic agent (antibiotics of the tetracycline family, insect hormone, progesterone antagonist, or immunosuppressor drug) to the drug-binding domain. The major limitations to the use of these systems for human gene and cell therapies are the toxicity of the inducer molecule and the immunogenicity of the chimeric transcription factor. Thus, the gene regulation systems should operate with clinically approved drugs with safety records that do not conflict with the therapeutic gene expression regimen. This work focuses on the characterization of the immunogenicity of a tetracycline-activated transcription factor commonly used in preclinical gene therapy, rtTA2-M2, and its impact on reporter gene expression. We demonstrate that intramuscular injection of plasmid or adenoviral vectors encoding rtTA-M2 in outbred primates generates a cellular and humoral immune response to this transcription factor. The immune response to rtTA2-M2 blunts the duration of the expression the rtTA2-M2-controlled transgene in primates, presumably by destruction of the cells that coexpress rtTA2-M2 and the reporter or therapeutic gene. This immune response may result directly from the vectors used in this study, which prompts the development of new gene transfer vectors enabling safe and efficient pharmacologic gene regulation in clinic.